In this study, we investigated the role S1PR1 and S1PR5 in astrocyte function by using the S1PR3-sparing drug BAF312 (Siponimod), which is currently in phase II clinical trials for secondary progressive MS. This evidence concerns the gene S1PR3 and myeloid sarcoma.